EYES

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them!

EYES Stock Pops on Biotech Merger Plans. 5 Things to Know.

EYES stock is up 15% today on news that Second Sight Medical is making a strategic acquisition. Here's what to know.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning! We've got another busy day ahead of us so let's get right into it with the biggest pre-market stock movers for Tuesday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, trader! We're halfway through the week and with that comes a look at the biggest pre-market stock movers for Wednesday!

EYES Stock: The Artificial Vision News That Has Investors Looking at Second Sight

EYES stock is set for another day of double-digit gains after the European patent agency approved the company's application.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Thursday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're starting off the day with a look at the pre-market stock market movers for Wednesday with the biggest winners and losers.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

We're back at it again with a look at the biggest pre-market stock movers for Wednesday and it's clear earnings season is here.

5 Heavily Shorted Stocks to Watch Carefully

Short-covering has become one of the hottest buzzwords of the year. Here are 5 stocks with some of the highest shorts on the market.

Most Shorted Stocks: Could EYES, BLNK, DISCA or CLVS Be the Next GameStop?

Investors are clamoring to find the next GameStop. Of the most shorted stocks right now, these are the candidates most primed for a squeeze.

Second Sight May Take Another Look at Giving Up Control

Second Sight Will Probably Take a Second Look at Giving Up Control. EYES stock will probably rise if the company backs off of the sale of 60% to Pixium Vision.

Let Second Sight Stock Give Back a Little More Before Jumping In

Add in the pending capital raise, and dilution concerns are on the table as well. Speculative mania over low-priced stocks may help it hold onto most of its gains. But, we could still see EYES stock fall to lower prices. So, what's the verdict? Wait for an additional dip (perhaps to the mid-to-upper single digits) before buying.

Second Sight Medical Products Is No Short Squeeze

EYES stock jumped higher off a very encouraging FDA approval but now is the time to apply a little more scrutiny to the Second Sight Medical investment.

FDA Approval Sheds New Light on Second Sight Medical Products

You won't believe your eyes when you see the ultra-bullish price action in EYES stock, along with the game-changing regulatory announcement.

EYES Stock: 12 Things for Second Sight Medical Investors to Know as Shares Keep Rocketing

Second Sight Medical Products (EYES) stock just can't stop soaring higher following approval from the FDA on Friday for one of its devices.

What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.

So what did the stock market do today? We watched a major turnaround in the stock market and saw a few winners and losers emerge.

EYES Stock: The Big FDA News That Has Second Sight Shares Soaring

Second Sight (EYES) stock is soaring higher Friday after announcing approval from the FDA for its Argus 2s Retinal Prosthesis System.

10 Healthcare Innovations That Will Change the World

Lots of companies are developing impressive, novel drugs and biotechnologies, but these healthcare outfits are close to reshaping how we view and think of health.

4 Health Care Equipment & Supplies Stocks to Sell Now

The ratings of 4 Health Care Equipment & Supplies stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").